Summary
33.26 0.58(1.76%)05/20/2024
Arvinas Inc (ARVN)
Arvinas Inc (ARVN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 6.42 | 8.06 | -8.82 | -27.70 | 92.97 | 39.16 | 74.26 | 113.89 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 34.33 | |
| Open | 32.39 | |
| High | 34.77 | |
| Low | 31.90 | |
| Volume | 863,667 | |
| Change | 2.07 | |
| Change % | 6.42 | |
| Avg Volume (20 Days) | 721,825 | |
| Volume/Avg Volume (20 Days) Ratio | 1.20 | |
| 52 Week Range | 13.57 - 53.08 | |
| Price vs 52 Week High | -35.32% | |
| Price vs 52 Week Low | 152.98% | |
| Range | 5.99 | |
| Gap Up/Down | -1.06 | |
Fundamentals | ||
| Market Capitalization (Mln) | 2,276 | |
| EBIDTA | -64,270,736 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 129.53 | |
| Book Value | 15.4970 | |
| Earnings Per Share | -3.7980 | |
| EPS Estimate Current Quarter | 2.8700 | |
| EPS Estimate Next Quarter | -0.6400 | |
| EPS Estimate Current Year | -3.5000 | |
| EPS Estimate Next Year | -3.0700 | |
| Diluted EPS (TTM) | -3.7980 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -8.1496 | |
| Return on asset (TTM) | -0.1226 | |
| Return on equity (TTM) | -0.3511 | |
| Revenue TTM | 22,586,260 | |
| Revenue per share TTM | 0.4780 | |
| Quarterly Revenue Growth (YOY) | 0.2220 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 21,801,777 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 17.6991 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 4.3455 | |
| Revenue Enterprise Value | 89.1843 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 52,871,600 | |
| Shares Float | 45,696,963 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 12.90 | |
| Institutions (%) | 84.04 | |
05/16 06:00 EST - globenewswire.com
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in combination with palbociclib were consistent with data previously reported at SABCS in December 2023 –
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in combination with palbociclib were consistent with data previously reported at SABCS in December 2023 –
05/09 16:42 EST - globenewswire.com
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress held from May 15-17, 2024, in Berlin, Germany. Vepdegestrant is a novel investigational PROTAC® estrogen receptor (ER) degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with early and locally advanced or metastatic ER positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress held from May 15-17, 2024, in Berlin, Germany. Vepdegestrant is a novel investigational PROTAC® estrogen receptor (ER) degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with early and locally advanced or metastatic ER positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.
05/07 09:16 EST - zacks.com
Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.97 per share versus the Zacks Consensus Estimate of a loss of $1.48. This compares to loss of $1.54 per share a year ago.
Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.97 per share versus the Zacks Consensus Estimate of a loss of $1.48. This compares to loss of $1.54 per share a year ago.
05/07 07:00 EST - globenewswire.com
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting –
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting –
05/02 11:01 EST - zacks.com
Why Earnings Season Could Be Great for Arvinas (ARVN)
Arvinas (ARVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Earnings Season Could Be Great for Arvinas (ARVN)
Arvinas (ARVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
05/01 13:00 EST - zacks.com
Arvinas (ARVN) Upgraded to Buy: What Does It Mean for the Stock?
Arvinas (ARVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Arvinas (ARVN) Upgraded to Buy: What Does It Mean for the Stock?
Arvinas (ARVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
04/26 11:05 EST - zacks.com
Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Arvinas (ARVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Arvinas (ARVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04/24 16:30 EST - globenewswire.com
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Randy Teel, Ph.D., to the newly created role of Chief Business Officer. Dr. Teel currently serves as Arvinas' interim Chief Financial Officer and Treasurer, and in his new role, he will remain a member of the Executive Committee reporting to Chairperson, President and Chief Executive Officer, John Houston, Ph.D. Dr. Teel will remain in these interim roles at Arvinas while the board of directors continues its search for a permanent Chief Financial Officer and Treasurer.
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Randy Teel, Ph.D., to the newly created role of Chief Business Officer. Dr. Teel currently serves as Arvinas' interim Chief Financial Officer and Treasurer, and in his new role, he will remain a member of the Executive Committee reporting to Chairperson, President and Chief Executive Officer, John Houston, Ph.D. Dr. Teel will remain in these interim roles at Arvinas while the board of directors continues its search for a permanent Chief Financial Officer and Treasurer.
04/11 11:31 EST - invezz.com
Arvinas inks over $1.0 billion deal with Novartis
Arvinas Inc (NASDAQ: ARVN) is in the green at writing after announcing a deal worth over $1.0 billion with Novartis (SWX: NOVN). Details of Arvinas – Novartis agreement Novartis will pay $150 million to the pharmaceutical company up front.
Arvinas inks over $1.0 billion deal with Novartis
Arvinas Inc (NASDAQ: ARVN) is in the green at writing after announcing a deal worth over $1.0 billion with Novartis (SWX: NOVN). Details of Arvinas – Novartis agreement Novartis will pay $150 million to the pharmaceutical company up front.
04/11 07:00 EST - globenewswire.com
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
– Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas' preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01 billion in development, regulatory, and commercial milestones, as well as tiered royalties –
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
– Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas' preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01 billion in development, regulatory, and commercial milestones, as well as tiered royalties –
04/09 09:51 EST - zacks.com
Is Arvinas (ARVN) Stock a Solid Choice Right Now?
Arvinas (ARVN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Is Arvinas (ARVN) Stock a Solid Choice Right Now?
Arvinas (ARVN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
03/18 16:40 EST - globenewswire.com
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
- Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - - Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) -
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
- Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - - Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) -
03/04 07:00 EST - globenewswire.com
Arvinas to Participate in Upcoming Investor Conferences
NEW HAVEN, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences:
Arvinas to Participate in Upcoming Investor Conferences
NEW HAVEN, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences:
02/28 09:31 EST - zacks.com
Is a Surprise Coming for Arvinas (ARVN) This Earnings Season?
Arvinas (ARVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Surprise Coming for Arvinas (ARVN) This Earnings Season?
Arvinas (ARVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
02/27 09:31 EST - zacks.com
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
Arvinas, Inc. (ARVN) came out with a quarterly loss of $2.53 per share versus the Zacks Consensus Estimate of a loss of $1.33. This compares to loss of $1.56 per share a year ago.
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
Arvinas, Inc. (ARVN) came out with a quarterly loss of $2.53 per share versus the Zacks Consensus Estimate of a loss of $1.33. This compares to loss of $1.56 per share a year ago.
02/27 07:00 EST - globenewswire.com
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471) in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting –
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471) in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting –
02/23 10:56 EST - zacks.com
Wall Street Analysts See a 30.21% Upside in Arvinas, Inc. (ARVN): Can the Stock Really Move This High?
The consensus price target hints at a 30.2% upside potential for Arvinas, Inc. (ARVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See a 30.21% Upside in Arvinas, Inc. (ARVN): Can the Stock Really Move This High?
The consensus price target hints at a 30.2% upside potential for Arvinas, Inc. (ARVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
02/21 13:01 EST - zacks.com
What Makes Arvinas, Inc. (ARVN) a Strong Momentum Stock: Buy Now?
Does Arvinas, Inc. (ARVN) have what it takes to be a top stock pick for momentum investors? Let's find out.
What Makes Arvinas, Inc. (ARVN) a Strong Momentum Stock: Buy Now?
Does Arvinas, Inc. (ARVN) have what it takes to be a top stock pick for momentum investors? Let's find out.
02/20 16:05 EST - globenewswire.com
Arvinas Announces Chief Financial Officer Transition
- Sean Cassidy leaving Arvinas as of February 29, 2024 - - Randy Teel, Ph.D. to assume the role of interim Chief Financial Officer - NEW HAVEN, Conn.
Arvinas Announces Chief Financial Officer Transition
- Sean Cassidy leaving Arvinas as of February 29, 2024 - - Randy Teel, Ph.D. to assume the role of interim Chief Financial Officer - NEW HAVEN, Conn.